Subscribe to RSS
DOI: 10.1055/s-0044-1788787
The Role of Calcitonin Gene-Related Peptide and Amylin in Pediatric Migraine
Funding This work was supported by the Balikesir University Scientific Research Project, 2021/141.
Abstract
Background Very few studies have examined the relationship between calcitonin gene-related peptide (CGRP) and amylin levels and the disease in patients with migraine. The purpose of this study was to compare blood CGRP and amylin levels between pediatric migraine patients and healthy controls and the relationship between CGRP and amylin levels and migraine attack frequency and duration.
Methods The study involved two separate groups—control and migraine. Thirty-two patients aged 6 to 18 years presenting to the Balikesir University Medical Faculty pediatric neurology clinic and diagnosed with migraine were included. The control group consisted of 32 patients without migraine presenting to the clinic during the same time frame. The patients' demographic data, personal and family histories, migraine type and frequency, headache severity, basic anthropometric measurements (height, weight, and body mass index), and physical and neurological examination findings were recorded. Migraine patients were classified as ictal if the collection of blood specimens coincided with the attack period and as interictal if this was performed between attacks.
Results No statistically significant differences in mean CGRP or amylin levels were determined between the groups (migraine ictal/interictal) or between the migraine patients (in terms of gender or attack frequency and duration).
Conclusion Elucidating the complex processes involved in the pathogenesis of migraine is important in terms of our ability to develop new treatments and therapeutic strategies. This study aimed to evaluate CGRP and amylin levels in patients with pediatric migraine (in the ictal and interictal periods) compared with those in healthy controls.
Ethical Approval
Approval for the study was granted by the local ethical committee prior to commencement (permission no: 2022/57).
Informed Consent
All patients were informed about the study and provided consent forms prior to enrolment.
Publication History
Received: 06 January 2024
Accepted: 14 July 2024
Article published online:
12 August 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38 (01) 1-211
- 2 Ailani J, Burch RC, Robbins MS. Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 2021; 61 (07) 1021-1039
- 3 Førland-Schill A, Berring-Uldum A, Debes NM. Migraine pathophysiology in children and adolescents: a review of the literature. J Child Neurol 2022; 37 (07) 642-651
- 4 Ashina M, Terwindt GM, Al-Karagholi MA-M. et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 2021; 397 (10283): 1496-1504
- 5 Pellesi L, Al-Karagholi MA-M, De Icco R. et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Netw Open 2021; 4 (08) e2118543
- 6 Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014; 94 (04) 1099-1142
- 7 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33 (01) 48-56
- 8 Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009; 49 (09) 1258-1266
- 9 Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia 2019; 39 (12) 1535-1543
- 10 Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140 (03) 827-831
- 11 Edvinsson L, Grell AS, Warfvinge K. Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci 2020; 70 (06) 930-944
- 12 Edvinsson L, Goadsby PJ, Uddman R. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal 2001; 1: 168-180
- 13 Irimia P, Martínez-Valbuena I, Mínguez-Olaondo A. et al. Interictal amylin levels in chronic migraine patients: a case-control study. Cephalalgia 2021; 41 (05) 604-612
- 14 Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. The origin of nausea in migraine-a PET study. J Headache Pain 2014; 15 (01) 84
- 15 Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med 2002; 346 (04) 257-270
- 16 Messlinger K. Migraine: where and how does the pain originate?. Exp Brain Res 2009; 196 (01) 179-193
- 17 Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010; 169 (02) 683-696
- 18 Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010; 30 (10) 1179-1186
- 19 Whitehouse F, Kruger DF, Fineman M. et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25 (04) 724-730
- 20 Hollander PA, Levy P, Fineman MS. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26 (03) 784-790
- 21 Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 2007; 150 (05) 633-640
- 22 Ghanizada H, Al-Karagholi MAM, Walker CS. et al. Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol 2021; 89 (06) 1157-1171
- 23 Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013; 81 (14) 1191-1196
- 24 Lee MJ, Lee SY, Cho S, Kang ES, Chung CS. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 2018; 19 (01) 53
- 25 Rees TA, Hendrikse ER, Hay DL, Walker CS. Beyond CGRP: the calcitonin peptide family as targets for migraine and pain. Br J Pharmacol 2022; 179 (03) 381-399
- 26 Yang Y, Ozawa H, Lu H. et al. Immunocytochemical analysis of sex differences in calcitonin gene-related peptide in the rat dorsal root ganglion, with special reference to estrogen and its receptor. Brain Res 1998; 791 (1-2): 35-42
- 27 Stucky NL, Gregory E, Winter MK. et al. Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache 2011; 51 (05) 674-692